GlassScriptPhysician profile
Kathryn Boylan
NPI 1275113961
$4,544.02
in general payments reported to CMS, 2019-2025
29 companies · $645 in 2025
The $645 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $461 · 2023: $1,592 · 2024: $1,846 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,033 · Education: $50.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,032.53 |
| Education | $50.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $520.98 | 2023-2025 | Rystiggo, Briviact, Fintepla |
| Csl Behring | $390.13 | 2023-2025 | Hizentra, Kcentra |
| Genentech USA, INC. | $387.89 | 2022-2025 | Evrysdi, Ocrevus, Activase |
| Novartis Pharmaceuticals Corporation | $344.42 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $264.57 | 2022-2025 | Hyqvia, Gammagard |
| Abbvie INC. | $262.02 | 2023-2024 | Botox |
| Acadia Pharmaceuticals INC | $235.29 | 2024-2025 | Nuplazid, Daybue |
| Eisai INC. | $228.66 | 2023-2025 | |
| Argenx US, INC. | $224.32 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Astrazeneca Pharmaceuticals LP | $212.97 | 2023-2024 | Andexxa, Wainua |
| Alexion Pharmaceuticals, INC. | $177.85 | 2022-2024 | Ultomiris, Soliris |
| Biogen, INC. | $165.34 | 2022-2024 | Vumerity, Tysabri, Spinraza |
| Otsuka America Pharmaceutical, INC. | $160.27 | 2023 | Nuedexta |
| Genzyme Corporation | $154.13 | 2023-2024 | |
| Amgen INC. | $123.67 | 2022-2024 | Uplizna, Repatha |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $106.88 | 2022-2023 | Mavenclad |
| Tanabe Pharma America, INC. | $90.57 | 2023 | |
| Merz Pharmaceuticals, LLC | $83.50 | 2022 | |
| Springworks Therapeutics, INC. | $76.32 | 2025 | Gomekli |
| Biohaven Pharmaceutical Holding Company LTD. | $67.51 | 2022 | |
| Pfizer INC. | $61.81 | 2023 | |
| Janssen Biotech, INC. | $60.76 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $24.39 | 2024 | |
| Neurelis, INC. | $23.27 | 2023 | Valtoco |
| Grifols USA, LLC | $23.03 | 2025 | Gamunex-C |
| Janssen Pharmaceuticals, INC | $20.44 | 2024 | Xarelto |
| Amicus Therapeutics, INC. | $19.96 | 2025 | |
| Esperion Therapeutics, INC. | $19.24 | 2023 | Nexletol |
| Microtransponder, INC. | $13.83 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Boylan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.